A Case of Organizing Pneumonia Associated with FOLFIRI Chemotherapy

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The combination chemotherapy of irinotecan with 5-fluorouracil and leucovorin (FOLFIRI regimen) was recently proven to be beneficial in patients with advanced colorectal cancer. Pulmonary toxicity is very rare in adverse effects of irinotecan. No case of organizing pneumonia (also known as bronchiolitis obliterans organizing pneumonia) associated with FOLFIRI chemotherapy has been reported. We experienced a case of a 62-year-old man who presented persistent dry cough and progressive dyspnea after receiving chemotherapy with FOLFIRI regimen. After surgical lung biopsy, the patient was diagnosed with FOLFIRI chemotherapy-induced organizing pneumonia which was successfully treated with steroid therapy.

Related collections

Most cited references 12

Record: found
Abstract: found
Article: not found

Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors.

Fatima Haggar, Robin P Boushey (2009)

In this article, the incidence, mortality, and survival rates for colorectal cancer are reviewed, with attention paid to regional variations and changes over time. A concise overview of known risk factors associated with colorectal cancer is provided, including familial and hereditary factors, as well as environmental lifestyle-related risk factors such as physical inactivity, obesity, smoking, and alcohol consumption.

0 comments Cited 700 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.

J. Douillard, D. Cunningham, A D Roth … (2000)

Irinotecan is active against colorectal cancer in patients whose disease is refractory to fluorouracil. We investigated the efficacy of these two agents combined for first-line treatment of metastatic colorectal cancer. 387 patients previously untreated with chemotherapy (other than adjuvant) for advanced colorectal cancer were randomly assigned open-label irinotecan plus fluorouracil and calcium folinate (irinotecan group, n=199) or fluorouracil and calcium folinate alone (no-irinotecan group, n=188). Infusion schedules were once weekly or every 2 weeks, and were chosen by each centre. We assessed response rates and time to progression, and also response duration, survival, and quality of life. Analyses were done on the intention-to-treat population and on evaluable patients. The response rate was significantly higher in patients in the irinotecan group than in those in the no-irinotecan group (49 vs 31%, p<0.001 for evaluable patients, 35 vs 22%, p<0.005 by intention to treat). Time to progression was significantly longer in the irinotecan group than in the no-irinotecan group (median 6.7 vs 4.4 months, p<0.001), and overall survival was higher (median 17.4 vs 14.1 months, p=0.031). Some grade 3 and 4 toxic effects were significantly more frequent in the irinotecan group than in the no-irinotecan group, but effects were predictible, reversible, non-cumulative, and manageable. Irinotecan combined with fluorouracil and calcium folinate was well-tolerated and increased response rate, time to progression, and survival, with a later deterioration in quality of life. This combination should be considered as a reference first-line treatment for metastatic colorectal cancer.

0 comments Cited 337 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib.

Masahiro Fukuoka, Koji Takeda, Isamu Okamoto … (2006)

Interstitial lung disease (ILD) is a serious adverse effect of gefitinib, but its prevalence and risk factors remain largely unknown. We examined the prevalence of and risk factors for gefitinib-induced ILD associated with practical use of the drug in Japanese with non-small-cell lung cancer (NSCLC). Clinical information was retrospectively assembled for NSCLC patients who started gefitinib treatment at affiliated institutions of the West Japan Thoracic Oncology Group between August 31 and December 31, 2002. Medical records of patients who developed pulmonary infiltrates were reviewed by a central committee of extramural experts for identification of patients with gefitinib-induced ILD. Multivariate logistic or Cox regression analysis was performed to identify independent predictive factors for ILD, antitumor response, and survival. Seventy cases of and 31 deaths from gefitinib-induced ILD were identified among 1,976 consecutively treated patients at 84 institutions, corresponding to a prevalence of 3.5% and mortality of 1.6%. Gefitinib-induced ILD was significantly associated with male sex, a history of smoking, and coincidence of interstitial pneumonia (odds ratios = 3.10, 4.79, and 2.89, respectively). Predictive factors for response were female sex, no history of smoking, adenocarcinoma histology, metastatic disease, and good performance status (PS), whereas predictive factors for survival were female sex, no history of smoking, adenocarcinoma histology, nonmetastatic disease, good PS, and previous chest surgery. ILD is a serious adverse effect of gefitinib in the clinical setting that cannot be ignored. However, patient selection based on sex and smoking history can minimize ILD risk and maximize the clinical benefit of gefitinib.

0 comments Cited 91 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Journal

Journal ID (nlm-ta): Tuberc Respir Dis (Seoul)

Journal ID (iso-abbrev): Tuberc Respir Dis (Seoul)

Journal ID (publisher-id): TRD

Title: Tuberculosis and Respiratory Diseases

Publisher: The Korean Academy of Tuberculosis and Respiratory Diseases

ISSN (Print): 1738-3536

ISSN (Electronic): 2005-6184

Publication date (Print): December 2014

Publication date (Electronic): 31 December 2014

Volume: 77

Issue: 6

Pages: 262-265

Affiliations

Department of Internal Medicine, Konkuk University Hospital, Konkuk University School of Medicine, Seoul, Korea.

Author notes

Address for correspondence: Sun Jong Kim, M.D. Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, Konkuk University Hospital, 120 Neungdong-ro, Gwangjin-gu, Seoul 143-729, Korea. Phone: 82-2-2030-7523, Fax: 82-2-2030-7748, sjkim@ 123456kuh.ac.kr

Article

DOI: 10.4046/trd.2014.77.6.262

PMC ID: 4286784

SO-VID: 78d1903b-225d-48c4-801b-d6f745553b23

License:

It is identical to the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/3.0/)

History

Date received : 23 January 2014

Date revision received : 28 July 2014

Date accepted : 29 August 2014

Comments

Comment on this article

scite_

Cited by 1

COVID-19 outbreak in Italy: Clinical-radiological presentation and outcome in three oncologic patients ☆
Authors: Davide Colombi, Flavio Bodini, Nicola Morelli …

See all cited by

A Case of Organizing Pneumonia Associated with FOLFIRI Chemotherapy

Read this article at

Abstract

Related collections

Inflamed lung in vitro co-culture models

Most cited references 12

Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors.

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.

Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib.

Author and article information

Journal

Affiliations

Author notes

Article

History

Categories

Comments

Comment on this article

Similar content 811

Cited by 1